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Abstract
Introduction: The aim of this study was to evaluate the effects and mechanisms
of Setarud (IMODTM) as a multi-herbal medicinal formula on a mouse model of
type 1 diabetes.
Material and methods: Autoimmune diabetes was induced by multiple low-dose
intraperitoneal injection of 40 mg/kg of streptozotocin (STZ) for five consecutive
days. IMODTM was administered at an effective dose of 20 mg/kg/day for 21
days. After 21 days of treatment, the pancreases of the animals were separated
and homogenized. In the pancreas tissue, the level of lipid peroxidation as
thiobarbituric acid reactive substances (TBARS), total antioxidant power as ferric
reducing ability of pancreas (FRAP), myeloperoxidase (MPO), and the
concentrations of interleukin-1 (IL-1β) and tumour necrosis factor-α (TNF-α)
were evaluated. Glucose changes were tested in the blood. Microscopic changes
in the pancreas were followed by histological examinations.  
Results: No significant difference was found between IMODTM and diabetic
control groups in blood glucose pattern. STZ-exposed mice showed a significant
increase in pancreatic TBARS, MPO, IL-1β, and TNF-α levels, along with
a significant decrease in FRAP value. Co-administration of IMODTM significantly
improved all the mentioned parameters disrupted by STZ administration except
for blood glucose and histological changes.
Conclusions: IMODTM could ameliorate oxidative and immunological distresses
of type-1 immunogenic diabetes but could not normalize blood glucose. Further
studies are recommended to clarify the effects of IMODTM on immunological
factors to address whether this new agent could be applied in diabetes
prevention or therapy. 
Key words: IMODTM, multiple low dose streptozotocin, diabetes, insulitis, antioxidant,
oxidative stress.
Introduction
Type 1 diabetes is an autoimmune disease characterized by infiltration
of lymphocytes or macrophages into the pancreatic islets and destruction
of β cells leading to hyperglycaemia. Environmental triggers such as viruses
or toxins in a genetically susceptible body may commence a series of
Corresponding author:
Prof. Mohammad Abdollahi
Faculty of Pharmacy, 
and Pharmaceutical
Sciences Research Centre
Tehran University of Medical
Sciences
Tehran 141761-4411, Iran
Phone/fax: +98 21 669 591 04
E-mail:
mohammad.abdollahi@
utoronto.ca
Basic research
1Faculty of Pharmacy, and Pharmaceutical Sciences Research Centre, Tehran University
of Medical Sciences, Tehran, Iran
2Endocrinology and Metabolism Research Centre, Tehran University of Medical Science,
Tehran, Iran
Submitted: 24 February 2009
Accepted: 12 May 2009
Arch Med Sci 2010; 6, 5: 663-669
DOI: 10.5114/aoms.2010.17078
Copyright © 2010 Termedia & Banach664 Arch Med Sci 5, October / 2010
Seyed Sajad Mohseni-Salehi-Monfared, Ebad Habibollahzadeh, Hooman Sadeghi, Maryam Baeeri, Mohammad Abdollahi
reactions and initiate an immune system
response. T cell lymphocytes play a major role in
beginning such a harmful process. Cytotoxic
cytokines such as tumour necrosis factor α (TNF-α)
and interleukin 1 (IL-1β) which are released from
activated T cells result in inflammation within the
pancreatic islets, called insulitis [1]. Following
insulitis, free radicals are induced that accelerate
the type 1 diabetes [2, 3].
Beside non-obese diabetic (NOD) mice and bio-
breeding (BB) rats, multiple low dose (MLD)
administration of streptozotocin (STZ) to mice is
used as a model of type 1 diabetes in animals. Five
days’ consecutive low dose injection of STZ to mice
starts an inflammatory response leading to insulitis
resulting in type 1 diabetes [4].
In management of type 1 diabetes, immuno  -
modulators such as azathioprine, cyclosporine,
nicotinamide, and new anti-cytokines or cytokine
inhibitors, have been successfully applied to diminish
lymphocytic infiltration to β cells and production of
pro-inflammatory TNF-α and IL-1β, and the immune-
mediated destruction of β-cells [5].
Previous studies have shown that some
antioxidants and radical scavenging agents could
counteract STZ-induced diabetes [6-11]. Preventive
effects of such therapies are explained by the role
of oxidative stress in pathophysiology of insulitis.
Furthermore, β cells have been shown to contain
fewer antioxidant enzymes including catalase,
glutathione peroxidase and superoxide dismutase
in comparison with other tissues which worsen the
destructive effect of oxidative stress [12]. 
IMODTM has been patented with the code of
WO/2007/087825 for its immunomodulatory and
anti-TNF-α capacities [13]. It is a three-component
herbal extract treated with chemical trace elements
and a special electromagnetic field. It was invented
briefly by preparing ethanolic herbal extract from
Rosa canina, Urtica dioica, and Tanacetum vulgare,
adding selenium and urea and having been exposed
to a pulsed electromagnetic field. The mechanism
implicated for the immunomodulating effect 
of IMODTM is increasing the amount of CD4 
T-lymphocytes and strong antioxidative and 
anti-TNF-α potential. In addition, toxicology tests
have demonstrated the safety of IMODTM [14].
In the present study the effect of IMODTM as
a novel natural immunomodulator with very
impressive antioxidative properties has been tested
in MLD STZ-induced mouse type 1 immunogenic
diabetes.
Materials and methods
Animals and Reagents
Eight to ten week old, male BALB/C mice (30-40 g)
were taken from the animal house of the institute.
They were kept in groups of 6 mice/cage. All
animals received care in accordance with the
national health guidelines and the design of the
study was approved by the animal experiments
ethics committee of Tehran University of Medical
Science. IMODTM was obtained from Pars Roos Co.
(Tehran). Blood glucose was measured using an
ACCU-CHEK glucometer (USA). Mouse TNF-α and
IL-1β ELISA kits were purchased from Nima-Pouyesh
Co. (Tehran).
Materials for measurement of thiobarbituric acid
reactive substances (TBARS), total antioxidant power
(ferric reducing ability of pancreas; FRAP),
myeloperoxidase (MPO), protein, and sample
preparation for histological assay were purchased
from Merck Chemical Co. (Tehran). Protease inhibitor
and STZ were obtained from Sigma-Aldrich (UK).
Treatment groups
Animals were divided randomly into four
treatment groups. Diabetes was induced in mice
by injection of STZ (40 mg/kg dissolved in citrate
buffer, pH 4.5) intraperitoneally for 5 consecutive
days in the second and fourth groups. Diabetic mice
in D-IM and D-C groups were treated every day with
an effective dose of IMODTM (20 mg/kg, IP) and
vehicle (normal saline) respectively for 21 days.
Animals receiving IMODTM treatment were injected
with STZ 30 min prior to IMODTM. The other two
groups (ND-C and ND-IM) received either normal
saline or IMODTM intraperitoneally for 21 days. Blood
glucose was measured on days 1, 7, 14 and 21 from
the tail vein. Insulin and C-peptide were not
measured because the blood sugar is a good
presenter of insulin status inside the murine body.
Hyperglycaemia was defined as a non-fasting blood
glucose level ≥ 11 mmol/l (200 mg/dl). Animals were
sacrificed on day 21 and pancreas samples were
removed for histological, biochemical, and cytokine
assays.
Determination of pancreatic MPO, TBARS,
FRAP, and cytokines
MPO assay
Pancreas biopsy was weighed before being
placed into phosphate buffer (pH = 7) containing
a protease inhibitor (PMSF), to achieve 100 mg/ml
concentration of tissue. Then it was homogenized
and centrifuged at 45 000 × g for 30 min. The
supernatant was removed and frozen at –80°C until
assay. To the sediment was added 10 ml of 50 mM
phosphate buffer (pH = 6) containing 0.5%
hexadecyl trimethyl ammonium bromide (HETAB)
and 10 mM EDTA, sonicated and centrifuged at
12 000 × g for 20 min. Finally, the supernatant was
removed and frozen at –80°C for MPO assay. During
analysis, 100 µl of preserved supernatant wasArch Med Sci 5, October / 2010 665
Efficacy of Setarud (IMODTM), a novel electromagnetically-treated multi-herbal compound, in mouse immunogenic type-1 diabetes
mixed with 2.9 ml phosphate buffer containing
0.167 mg/ml O-dianisidine dihydrochloride and
0.0005% hydrogen peroxide. MPO activity was
measured spectrophotometrically as the change in
absorbance at 460 nm. Results are presented as
milliunits per mg protein [15].
TBARS assay
TBARS of the pancreas was determined from the
preserved supernatant as mentioned above. Of the
supernatant, 0.5 ml was added to 2.5 ml trichloro  -
acetic acid (20%); after 10 min at room temperature,
the sample was centrifuged (10 000 × g, 10 min),
and the sediment was added to a reaction mixture
consisting of 2.5 ml sulfuric acid 0.05 M, 3 ml of
TBA 0.2%, and sodium sulfate 2 M. The mixture was
incubated at 100°C for 30 min. After cooling to room
temperature, 3 ml of n-butanol was added to the
sample and centrifuged (10 000 × g, 10 min) and
then the absorbance was measured at 532 nm.
Results are expressed as nmol/mg protein [15]. 
FRAP assay
Of the above-mentioned preserved supernatant,
0.1 ml was added to a reaction mixture consisting
of 2.5 ml of acetate buffer (300 mmol/l, pH = 3.6),
0.25 ml of ferric chloride (20 mmol/l), 0.25 ml of TPTZ
(2,4,6-tripyridyl-s-triazine 10 mmol/l into hydrochloric
acid 40 mM), then it was incubated for 10 min at
37°C. The absorbance was measured at 593 nm.
Results are expressed as µmol/mg protein [15].
Protein assay
Total protein in pancreas samples was analysed
using the Bradford protein assay. Briefly, diluted
samples were mixed with Bradford reagent dye and
after 5 min the absorbance was measured at 595 nm
by the spectrophotometer. Albumin was used as
standard. 
Cytokines assay
The concentration of IL-1β and TNF-α in the
preserved supernatant of the pancreas (described
above) was determined using specific mouse ELISA
kits. According to the procedure, a coloured product
is formed in proportion to the amount of cytokine
present in samples, and after adding stop solution
to terminate the reaction, absorbance was measured
at 450 nm as the primary wavelength and 620 nm
as the reference wavelength. TNF-α and IL-1β levels
were expressed as pg/µg protein. Details of the
procedure have been described previously [15].
Histological assay
To evaluate the severity of insulitis at day 21,
a portion of pancreas was fixed in 10%
formaldehyde, embedded in paraffin, sectioned at
4.5 µm, and stained with haematoxylin-eosin.
Insulitis was graded 0 to 3, according to infiltration
of islets with lymphocytes as none = 0, less than
10% = 1, 10 to 50% = 2, and more than 50% = 3 [16].
Statistical analyses
Statistical analyses of the data were performed
using StatsDirect statistical software version 2.7.2
(9/6/2008). One way ANOVA was followed by post-
hoc Newman-Keuls multiple comparisons test.
Kruskal-Wallis test was used to compare
histological scores. A p value of < 0.05 was regarded
as significant.
Results
Effect of IMODTM on blood glucose 
After injection of STZ, blood glucose in both
treated groups was raised. Though blood glucose did
not attain the diabetic range (more than 200 mg/dl)
after 7 days, all animals in both STZ-treated groups
were diabetic when tested after 14 days. As shown
in Figure 1, there was no difference between
diabetic animals given IMODTM and diabetic
controls in blood glucose pattern. Also there was
no significant difference in blood glucose between
the two non-diabetic (IMODTM alone and control)
groups. IMODTM treatment had no significant effect
on blood glucose changes (Figure 1).
Effect of IMODTM on pancreatic oxidative stress
Following administration of IMODTM, oxidative
stress indicators including MPO activity, FRAP, and
TBARS were measured in pancreatic specimens of
animals at the end of the study (day 21). Figure 2A
shows MPO activity between groups. There was
Day 1 Day 7 Day 14 Day 21
* *
Figure 1. Non-fasting blood glucose changes in
experimental groups. Difference in glucose value on
days 7, 14, and 21 in D-IM and D-C compared with
those of ND-C and ND-IM is significant at p < 0.01
(*). There was no difference between the diabetic
group given IMODTM and diabetic controls in blood
glucose pattern
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a significant difference between diabetic and other
groups in MPO activity (p < 0.05). There was
a significant decrease of MPO activity in IMODTM
-treated diabetic mice compared to the diabetic
control group (p < 0.05).
Data of TBARS used to quantify lipid
peroxidation in the mice pancreases are seen in
Figure 2B. TBARS was elevated in STZ-treated
(diabetic control) mice compared to other groups
(p < 0.05). IMODTM treatment reduced TBARS in the
pancreas of both diabetic and non-diabetic mice 
(p < 0.05). 
Data of changes in FRAP used to assess total
antioxidant power are shown in Figure 2C. There
was increased FRAP among IMODTM-treated
animals. Total antioxidant power was the least in
the diabetic control group (p < 0.05) while it was
the greatest in both IMODTM-treated groups as
compared with non-diabetic mice (p < 0.05).   
Effect of IMODTM on pancreatic cytokines 
Two Th1 cytokines, IL-1β and TNF-α, were
assessed at the end of the study in the pancreas
sample of mice. Results are shown in Figure 3. As
seen, there are significant differences in
concentration of both cytokines in diabetic mice.
IMODTM could lead to lower production of IL-1β
and TNF-α in pancreas of treated mice.
Histological changes 
Histological insulitis scores were higher in the
pancreatic samples of diabetic mice than those of
the controls on day 21 (p < 0.05). Insulitis index
(Figure 4) in the IMODTM-treated group was not
significantly lower than diabetic control mice. 
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Figure 2. Pancreatic level of oxidative stress markers
in experimental groups on day 21. IMODTM
(20 mg/kg/d, IP) decreased MPO activity (A) and lipid
peroxidation, assessed by TBARS concentration (B),
in pancreas samples of treated mice. Total
antioxidant power (FRAP) of pancreatic tissue
increased in IMODTM treated groups (C)
*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
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Figure 3. Pancreatic level of Th1 cytokines TNF-α and
IL-1β in experimental groups on day 21. IMODTM
(20 mg/kg/d, IP) prevented increase in TNF-α (A) and
IL-1β (B) in pancreas sample of treated mice
*p < 0.01 comparing with ND-C; **p < 0.01 comparing with D-C
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Discussion
Our data revealed that administration of IMODTM
could ameliorate oxidative stress indicators and
proinflammatory cytokines in pancreas of MLD STZ-
induced type 1 diabetes in BALB/c mice. However,
this effect did not lead to decrease in blood glucose
or histological benefit.  
MLD STZ-induced diabetes in mice is similar to
type 1 diabetes in humans. In this model, infiltration
of macrophages and lymphocytes into the pancreas
leads to insulitis and activation of mononuclear cells
at the site of inflammation then production of nitric
oxide (NO), which is cytotoxic to β cells [17].
Insulitis, mononuclear infiltration and inflammatory
reactions all happen due to the immunological
response that has an essential role in type 1
diabetes. Th1 lymphocytes which belong to CD4+ T
cells produce cytokines that primarily stimulate cell-
mediated immunity. Both IL-1β and TNF-α as Th1
secreted cytokines have proinflammatory effects.
Th2 cells secrete cytokines such as IL-4, IL-6 and 
IL-1β0, which are believed to play a role in
stimulation of humoral immunity [18].
It is now well known that Th1 with its
inflammatory cytokines is responsible for β cell
damage in type 1 diabetes. In immunological
mechanisms of type 1 diabetes, after processing of
specific β cell proteins by antigen presenting cells
(APCs) such as macrophages and dendritic cells,
these proteins act as autoantigens. Presented
antigens interact via major histocompatibility
complex (MHC) class II molecules on the surface of
CD4+ T cells, which leads to production of cytokines
such as IL-1β2 from APCs. IL-1β2 promotes CD4+ cells
to differentiate into Th1 cells. Th1 characteristic
cytokines inhibit Th2 cells’ production of their
cytokines (IL-4, IL-1β) and activate macrophages 
and both CD4+ and CD8+ cytotoxic T cells. Finally,
these activated cells destroy β cells via their cytokines
(TNF-α and IL-1β) or by producing free radicals (H2O2,
O2 and NO) especially from macrophages [1].
The idea of immunogenic prevention of type 1
diabetes has been evaluated in many different
studies. Th2 cytokines induction [19, 20] as well as
Th1 cytokines inhibition [21, 22] has been shown to
prevent diabetes in mice. This evidence also
suggests that a decrease in Th1/Th2 cell ratio could
prevent immunogenic occurrence of diabetes by
the aforementioned mechanisms.
On the other hand, previous studies have
demonstrated that oxidative stress plays a key role
in pathology and progression of type 1 diabetes [23].
Various methods to overcome oxidative stress
including antioxidant agents have been recruited
to attenuate the development of hyperglycaemia
in diabetic mouse models [24, 25].
The present study hypothesis was that IMODTM
as a newly-introduced drug for management of
AIDS patients by increasing CD4+ T cells could
probably prevent STZ-induced mice from
developing type 1 diabetes. IMODTM contains three
herbal extracts, Rosa canina, Tanacetum vulgare
and Urtica dioica. Urtica dioica leaf extract contains
active blends that diminish TNF-α and other
inflammatory cytokines [26]. It has been shown
that Urtica leaf also reduces IL-1β by inhibiting the
genetic transcription factor that activates TNF-α
and IL-1β in the synovial tissue that lines the joint
[27]. The effect of Urtica dioica on diabetes has
been previously considered [38]. It has been shown
that Urtica leaf extract could improve type 2
diabetes in STZ-induced mice by increasing
secretion of insulin [39]. Rosa canina extract
possesses abundant antioxidant agents containing
vitamin C, vitamin E, flavanoids, and some
bioactive compounds which cause this plant to
have anti-inflammatory and radical scavenging
properties [30]. This herb is used in conventional
therapy in different conditions. Tanacetum vulgare
is also another herb that has antioxidant and anti-
inflammatory characteristics and some traditional
uses in medicine [31, 32]. 
However, the present results support the
hypothesis indicating positive effects of IMODTM
on oxidative stress and proinflammatory status of
the pancreas most probably due to combinational
effects of this herbal mixture, but this benefit was
not accompanied by complete improvement of
blood glucose or reduction of insulitis scores. At the
moment, there are no published data on the
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Figure 4. Histopathology study of pancreatic islets. Insulitis was graded 0 to 3, according to infiltration of islets with
lymphocytes as none = 0 (A), less than 10% = 1 (B), 10 to 50% = 2 (C), and more than 50% = 3 (was not seen in our
study groups). H&E (200 ×)668 Arch Med Sci 5, October / 2010
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mechanisms by which IMODTM alters the immune
system. It has only been shown that IMODTM
increases CD4+ T cells, but the type of CD4+ cells
(Th1 or Th2) is not clearly understood.
Regarding the immunological pathogenesis of
type 1 diabetes, if Th1 outweigh Th2, the disease
will proceed, but if Th2 cells are more differentiated
than Th1 ones, the disease will be suppressed. As
a limitation of the present study, we did not address
which of them was higher in the blood or
pancreatic sample of specimens, but our results
showed that IL-1β and TNF-α were lower in the
pancreas of the IMODTM-treated group. Therefore,
it can be concluded that even though IMODTM
reduced Th1 cytokines in the pancreas, total
domination of Th1 over Th2 remained stable,
resulting in incomplete prevention of diabetes in
the IMODTM-receiving group.
Nevertheless, our results are not in congruence
with comparable studies [33] reporting that
reduction of proinflammatory cytokines and
oxidative stress leads to prevention of diabetes and
improvement of glycaemia levels. However, these
incongruent data might have resulted from
combinatory effects of the herbs and the elements
present in the mixture of IMODTM. As a matter of
fact, as supported by the literature, it is not
surprising to observe a reduction of oxidative stress
without a hypoglycaemic effect. The same effects
in human diabetes have also been reported and are
expectable [34-38]. In fact, in the immunogenic
model of type 1 diabetes, the blood lowering effect
of any compound is mainly mediated through
insulin-like effects. Therefore, anti-oxidants or anti-
cytokines usually prevent complications or further
progress of the disease and thus cannot clear whole
disease because some portions of β-cells have 
been destroyed by STZ irreversibly [3]. Further
studies are needed to clarify the effects of IMODTM
on immunological factors to address whether this
new agent could be applied in diabetes prevention
or therapy.
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